PULMOTECT
Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). It was founded in 2007 and is headquartered in Houston, Texas.
PULMOTECT
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2007-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.pulmotect.com
Total Employee:
1+
Status:
Active
Contact:
7135799226
Email Addresses:
[email protected]
Total Funding:
28.35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Jefferson River Capital
Jefferson River Capital investment in Series B - Pulmotect
Fannin Innovation Studio
Fannin Innovation Studio investment in Series B - Pulmotect
Aquinas
Aquinas investment in Series B - Pulmotect
Houston Angel Network
Houston Angel Network investment in Series A - Pulmotect
Fannin Innovation Studio
Fannin Innovation Studio investment in Series A - Pulmotect
National Institutes of Health
National Institutes of Health investment in Grant - Pulmotect
National Heart, Lung and Blood Institute
National Heart, Lung and Blood Institute investment in Grant - Pulmotect
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Pulmotect
Official Site Inspections
http://www.pulmotect.com Semrush global rank: 5.76 M Semrush visits lastest month: 1.45 K
- Host name: wh1.tomohost.com
- IP address: 209.59.160.36
- Location: Lansing United States
- Latitude: 42.7348
- Longitude: -84.6245
- Metro Code: 551
- Timezone: America/Detroit
- Postal: 48917
More informations about "Pulmotect"
Pulmotect - Crunchbase Company Profile & Funding
Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast …See details»
Our Company - Pulmotect, Inc.
Pulmotect is pioneering an immunomodulatory and “pathogen agnostic” approach to preventing and treating respiratory complications by harnessing the power of the innate immune system. …See details»
Pulmotect Company Profile | Management and Employees List
Pulmotect Profile and History Pulmotect is developing PUL-042, a clinical stage, first-in-class, inhaled, immunomodulatory agent. A synergistic agonist that amplifies the innate immune …See details»
Pulmotect Company Profile 2024: Valuation, Funding
Who are Pulmotect’s investors? Axil Capital Partners, SkyWalker Property Partners, United States Department of Defense, Gershon Capital, and Jefferson River Capital are 5 of 11 investors who have invested in Pulmotect. Data …See details»
PULMOTECT, INC. Company Profile | Houston, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for PULMOTECT, INC. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
PULMOTECT, INC - VentureRadar
Develops host-directed, pathogen-agnostic biopharmaceutical products to reduce morbidity and mortality in patients with severe respiratory diseases, offering broad-spectrum, fast-acting …See details»
Pulmotect Company Profile - Office Locations, Competitors, …
Pulmotect has 5 employees at their 1 location and $11.9 m in total funding,. See insights on Pulmotect including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Pulmotect | Life Sciences PA
Pulmotect is pioneering an immunomodulatory and “pathogen agnostic” approach to preventing and treating respiratory complications by harnessing the power of the innate immune system. …See details»
Overview – Pulmotect, Inc.
ADVANCEMENTS. Technology composed of a synergistic combination of two synthetic molecules; Technology published in multiple leading peer-reviewed journals; Strong and …See details»
Pulmotect - Overview, News & Similar companies | ZoomInfo.com
Dec 7, 2021 Who is Pulmotect. Pulmotect is developing PUL-042, a clinical stage, first-in-class, inhaled, immunomodulatory agent. A synergistic agonist that amplifies the innate immune …See details»
Pulmotect - Company Profile - Tracxn
Oct 30, 2024 Pulmotect ranks 26th among 73 active competitors. 35 of its competitors are funded while 10 have exited. Overall, Pulmotect and its competitors have raised over $2.38B …See details»
Pulmotect - Contacts, Employees, Board Members, Advisors
Organization. Pulmotect . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. ... Pulmotect has 1 …See details»
Pulmotect - Funding, Financials, Valuation & Investors - Crunchbase
Pulmotect is funded by 7 investors. Jefferson River Capital and Fannin Innovation Studio are the most recent investors. Pulmotect has a post-money valuation in the range of $1M to $10M as …See details»
Scott Brenton - President & Chief Operat.. - Pulmotect - ZoomInfo
President & Chief Operating Officer at Pulmotect. Scott Brenton is the President & Chief Operating Officer at Pulmotect based in Houston, Texas. Previously, Scott was the Odyssey …See details»
Pulmotect Provides Results from Two Randomized, Placebo …
Houston, TX (November 30, 2021) – Pulmotect, Inc., a clinical-stage biotechnology company, announced results from the second of two Phase 2 clinical trials undertaken in the United …See details»
Houston biotech company is creating a drug that could fight the ...
Jan 31, 2020 A drug being developed by a Houston biopharmaceutical company eventually could help combat what the World Health Organization has proclaimed a global health …See details»
Pulmotect Provides Results from Two Randomized, Placebo …
Dec 2, 2021 HOUSTON--(BUSINESS WIRE)--Pulmotect, Inc., a clinical-stage biotechnology company, announced results from the second of two Phase 2 clinical trials undertaken in the …See details»
Our Pipeline – Pulmotect, Inc.
We are advancing our lead program, PUL-042, a first in class, patent protected, inhaled therapy that activates the innate immunity of the lungs for multiple indications.See details»
Pulmotect Reports Positive Topline Results from Randomized, …
Sep 24, 2021 HOUSTON--(BUSINESS WIRE)--Pulmotect, Inc., a clinical-stage biotechnology company, announced positive topline results from the first of two Phase-2 clinical trials …See details»